Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 pCR is related to combination of CYP1B1 and ERCC1 polymorphisms when adjusted on ER status

From: ERCC1 and CYP1B1 polymorphisms as predictors of response to neoadjuvant chemotherapy in estrogen positive breast tumors

CYP1B1 (Leu432Val) ERCC1 (Asn118Asn) N pCR OR 95% CI P value
n %a
CC TT 19 2 10.5 1 Reference  
CC CT 22 11 50.0 16.1 (2.3–112) 0.005
CC CC 6 1 16.7 2.8 (0.16–47) 0.48
CG TT 15 1 6.7 0.41 (0.03–5.6) 0.51
CG CT 20 2 10.0 0.77 (0.09–6.8) 0.81
CG CC 10 2 20.0 2.4 (0.24–25) 0.45
GG TT 6 1 16.7 0.89 (0.06–13.5) 0.93
GG CT 8 3 37.5 4.4 (0.46–41) 0.20
GG CC 7 2 28.6 3.1 (0.28–34) 0.35
ER−   42 15   1 Reference  
ER+   71 10   0.12 (0.03–0.43) 0.001
  1. Significant results are shown in italic.
  2. pCR pathological complete response.
  3. aPercentages of evaluable patients.